150 related articles for article (PubMed ID: 22052369)
1. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.
Ferro M; Giuberti G; Zappavigna S; Perdonà S; Facchini G; Sperlongano P; Porto S; Di Lorenzo G; Buonerba C; Abbruzzese A; Altieri V; Caraglia M
Oncol Rep; 2012 Feb; 27(2):409-15. PubMed ID: 22052369
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
[TBL] [Abstract][Full Text] [Related]
3. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Li R; Li Y; Song J; Gao K; Chen K; Yang X; Ding Y; Ma X; Wang Y; Li W; Wang Y; Wang Z; Dong Z
BMC Urol; 2020 Jul; 20(1):97. PubMed ID: 32660456
[TBL] [Abstract][Full Text] [Related]
4. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
Lightfoot AJ; Breyer BN; Rosevear HM; Erickson BA; Konety BR; O'Donnell MA
Urol Oncol; 2014 Jan; 32(1):35.e15-9. PubMed ID: 23510863
[TBL] [Abstract][Full Text] [Related]
5. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells.
Takeuchi H; Mmeje CO; Jinesh GG; Taoka R; Kamat AM
Oncol Rep; 2015 Nov; 34(5):2738-44. PubMed ID: 26323344
[TBL] [Abstract][Full Text] [Related]
6. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Cockerill PA; Knoedler JJ; Frank I; Tarrell R; Karnes RJ
BJU Int; 2016 Mar; 117(3):456-62. PubMed ID: 25682834
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Addeo R; Caraglia M; Bellini S; Abbruzzese A; Vincenzi B; Montella L; Miragliuolo A; Guarrasi R; Lanna M; Cennamo G; Faiola V; Del Prete S
J Clin Oncol; 2010 Feb; 28(4):543-8. PubMed ID: 19841330
[TBL] [Abstract][Full Text] [Related]
8. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer.
Breyer BN; Whitson JM; Carroll PR; Konety BR
Urol Oncol; 2010; 28(5):510-4. PubMed ID: 19171491
[TBL] [Abstract][Full Text] [Related]
9. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
Tuinmann G; Hegewisch-Becker S; Zschaber R; Kehr A; Schulz J; Hossfeld DK
Anticancer Drugs; 2004 Jul; 15(6):575-9. PubMed ID: 15205599
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
Zoli W; Ricotti L; Tesei A; Ulivi P; Gasperi Campani A; Fabbri F; Gunelli R; Frassineti GL; Amadori D
Clin Cancer Res; 2004 Feb; 10(4):1500-7. PubMed ID: 14977854
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
Daniels MJ; Barry E; Milbar N; Schoenberg M; Bivalacqua TJ; Sankin A; Kates M
Urol Oncol; 2020 Feb; 38(2):40.e17-40.e24. PubMed ID: 31473090
[TBL] [Abstract][Full Text] [Related]
13. Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
Huang XL; Zhang H; Yang XY; Dong XY; Xie XY; Yin HB; Gou X; Lin Y; He WY
Anticancer Drugs; 2017 Jul; 28(6):596-602. PubMed ID: 28430744
[TBL] [Abstract][Full Text] [Related]
14. Experimental study of combination therapy with S-1 against pancreatic cancer.
Yoshizawa J; Takizawa A; Takeuchi O; Hiraku O; Sasaki K; Morimoto Y; Atsuda K; Inoue G; Suzuki Y; Asanuma F; Yamada Y
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1211-9. PubMed ID: 19337733
[TBL] [Abstract][Full Text] [Related]
15. Interaction between gemcitabine and mitomycin-C in vitro.
Aung TT; Davis MA; Ensminger WD; Lawrence TS
Cancer Chemother Pharmacol; 2000; 45(1):38-42. PubMed ID: 10647499
[TBL] [Abstract][Full Text] [Related]
16. Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
Gao X; Liu J; Fan D; Li X; Fang Z; Yan K; Fan Y
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935059
[TBL] [Abstract][Full Text] [Related]
17. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
Chen M; Jiang Y; Cai X; Lu X; Chao H
Int Immunopharmacol; 2021 Sep; 98():107829. PubMed ID: 34119916
[TBL] [Abstract][Full Text] [Related]
18. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
19. Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer.
Li L; Zhao SL; Yue GGL; Wong TP; Pu JX; Sun HD; Fung KP; Leung PC; Han QB; Lau CBS; Leung PS
Phytomedicine; 2018 May; 44():56-64. PubMed ID: 29895493
[TBL] [Abstract][Full Text] [Related]
20. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Kornek GV; Schuell B; Laengle F; Gruenberger T; Penz M; Karall K; Depisch D; Lang F; Scheithauer W
Ann Oncol; 2004 Mar; 15(3):478-83. PubMed ID: 14998852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
